PODCAST · science
BiotechTV - News
by BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
-
HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.
-
HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA
CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.
-
HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology
He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.
-
HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune
Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors…
more -
HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."
Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure.
-
HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9
Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.
-
HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader
CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI.
-
HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications
CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis.
-
HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while
He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.
-
HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch
Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year.
-
HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator
OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile.
-
HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech
He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector.
-
HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab
CEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate believes its Nectin 4 is well differentiated and compelling.
-
HCW 2026: Trevi Therapeutics was founded under the premise that cough is a brain problem, not a lung problem - it seems to be playing out in the clinic
Co-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an overview of the clinical timelines.
-
HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better
Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs
-
HCW 2026: Switzerland based Oculis focuses today on neuro-ophthalmology, which has led them to a pivotal trial in optic neuritis and key mid-stage data coming this year in dry eye disease
CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye.
-
Bay Area based Shennon Biotechnologies announced a new CEO today, Cyril Konto, and a $12M raise to advance its T-cell engager programs
It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.
-
UC Berkeley's Gokul Upadhyayula and Eric Betzig are building AI to interpret detailed movies of living cells captured by their MOSAIC microscope
The work could help guide drug discovery and development by revealing how disease disrupts cells.
-
Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases
Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.
-
Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology
Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the lead program targets hepatocellular carcinoma) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.
-
Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.
-
Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA
He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.
-
Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run...
-
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent...
-
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and...
-
Pareto Securities Healthcare Conference: Hansa Biopharma has a December 19 PDUFA date with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant
CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.
-
Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys
CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.
-
A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe
Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European…
more -
Sweden's BioArtic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for it brain transporter technology advancing
CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in...
-
Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO
Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.
-
Two fathers of children with rare diseases talk about starting biotech companies to try to create new therapies for their family members and others
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome.
-
LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation…
more -
U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences
Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
-
U.S. Science Summit: Patient perspectives with sickle cell patient advocate Jimi Olaghere and cystic fibrosis advocate Bob Coughlin
Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis.
-
U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public
Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the...
-
U.S. Science Summit: Flagship Pioneering Founder & CEO Noubar Afeyan discusses his early days in Cambridge and the opportunities it afforded him, science communication, immigrants, and more
He describes how science 'keeps you young' because it always based on what you don't know. He urges scientists to stay humble when talking about science to the public because things can change, and he shares stories from his career and offers advice on how to keep the United States globally...
-
U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan
Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language of expertise, and women in leadership.
-
U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience
Moderated by BiotechTV's Chloe Kirk, Gabriel Astorga (@GoodOlGab), Maynard Okereke (@HipHopScienceShow), and Alex Dainis (@AlexDainis) describe how the got started posting about science on social media and how they grew their audiences to what they are today. Plus, advice for companies and...
-
U.S. Science Summit: BiotechTV's Science Correspondent Chloe Kirk introduces the audience to the science communicator social media all-stars who were in attendance at the summit
The combined following of the group reaches approximately 3 million people on Instagram and TikTok.
-
U.S. Science Summit: Listen to BiotechTV founder Brad Loncar's opening remarks at the inaugural U.S. Science Summit
He describes the format and goals of the event.
-
U.S. Science Summit: Three leading biotech CEOs share the latest on biotech innovation and discuss how the United States can stay on top of an increasingly competitive global landscape
Moderated by MassBio CEO Kendalle Burlin O'Connel, Kymera Therapeutics CEO Nello Mainolfi, CRISPR Therapeutics CEO Samarth Kulkarni, and Ginkgo Bioworks CEO Jason Kelly discuss their companies' innovations (protein degradation, CRISPR gene editing, and autonomous labs), how the U.S. can increase...
-
U.S. Science Summit: Dr. Elias Zerhouni discusses the source of what made the United States strong in medical research decades ago and what is at stake to keep supporting it today
Dr. Zerhouni, the Founder and Chair of ModeX Therapeutics and Former NIH Director, talks about investments in science that started with Vannevar Bush, current day NIH funding, adding a political element to the grant making process, science communication, and more.
-
ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take…
more -
ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications
Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps...
-
London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors
Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.
-
Rapport Therapeutics has derived what it believes is 'unprecedented' early efficacy for its precision neuroscience treatment in focal onset seizures - its confidence comes from a unique trial design
CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and...
-
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
-
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
-
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a patient's rehab and might potentially have...
-
Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, and why he disagrees with the idea of 'hunkering...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
Loading similar podcasts...
Frequently Asked Questions
How many episodes does BiotechTV - News have?
BiotechTV - News currently has 484 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is BiotechTV - News about?
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
How often does BiotechTV - News release new episodes?
BiotechTV - News publishes regularly with 484 episodes available. Check the episode list for the typical release schedule.
Where can I listen to BiotechTV - News?
You can listen to BiotechTV - News on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts BiotechTV - News?
BiotechTV - News is created and hosted by BiotechTV.
URL copied to clipboard!